Hair Experts Report Varying Steroid Techniques for Alopecia
METHODOLOGY:
Researchers surveyed 28 dermatologists with hair expertise using a 77-question REDCap survey.
Participants averaged 17.7 years of experience, with completion of residency between 1985 and 2022.
The response rate was 75% (21 experts completed the survey).
The survey assessed ILC injection techniques across alopecia types, including facial alopecia.
TAKEAWAY:
For nonscarring alopecia, 5 mg/mL was the most common ILC dose (85.7%), followed by 2.5 mg/mL (38.1%); 95.2% of experts injected between 1 and 1.5 mL per session, 95.2% used a 30-gauge needle, and 95.2% injected in a grid pattern.
Most experts (71.4%) employed identical ILC techniques for both scarring and nonscarring alopecia, with 61.9% and 60%, respectively, preferring 6-week treatment intervals. The most common ILC dose for scarring alopecia was 5 mg/mL (60%), followed by 7.5 mg/mL (40%) and 10 mg/mL or more (40%).
For facial alopecia, 80% of experts used a lower concentration of 2.5 mg/mL, and 90% typically performed 3-4 sessions.
For nonscarring alopecia, experts suggested injecting parallel to the direction of hair growth to reduce pain and avoid follicle damage, and for scarring alopecia, they recommended starting with peripheral injections and moving toward the center of the lesion. For facial alopecia, experts recommended shallow injections and avoiding visible vessels to prevent atrophy and bruising.
IN PRACTICE:
'Our findings reveal general agreement amongst experts on the use of ILCs for alopecia; however, variation remains in concentration, injection spacing, and treatment duration, especially for facial and scarring alopecia,' the study authors wrote. Although a Delphi study 'could help standardize' ILC treatment approaches, they added, their results 'provide practical guidance for dermatologists on intralesional corticosteroid techniques for the treatment of various alopecia types.'
SOURCE:
This study was led by Noelle Desir, Department of Dermatology, University of Pennsylvania, Philadelphia, and was published online on June 3 in JAAD International .
LIMITATIONS:
Limitations included the hair expert identification process and potential response bias in the survey.
DISCLOSURES:
This study did not receive any funding. One study author reported serving as a consultant, advisory board member, speaker, and investigator for various pharmaceutical and cosmetic companies, including AbbVie, Arcutis Biotherapeutics, Pfizer, and L'Oréal, and also reported receiving royalties from McGraw Hill. Another author reported serving as an advisory board member for Beiersdorf. The remaining authors reported no conflicts of interest.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
20 minutes ago
- Yahoo
Alcohol use is up among women — and health consequences have followed
The risk that alcohol poses to women's health has mounted over the last two decades, as women have begun to drink more frequently and in larger quantities. Alcohol-related deaths among women more than doubled from 1999 to 2020. And deaths from alcohol-related hepatitis, a disease resulting in severe liver inflammation, nearly tripled among women over the same time period. A new study, published Wednesday in the medical journal Clinical Gastroenterology and Hepatology, similarly points to an elevated risk of alcohol-related liver disease among women. The condition encompasses various types of liver damage due to excessive alcohol consumption. It spans early-stage inflammation to severe scarring, known as cirrhosis, which can lead to liver failure. Women are more susceptible than men to alcohol-related liver disease for several reasons. For one, their bodies tend to have less water weight and a higher percentage of body fat. That combination increases the concentration of alcohol in their blood, which the liver then has to process. Compared with men, women also naturally have lower levels of an enzyme called alcohol dehydrogenase, which helps the body metabolize alcohol. That again leads to higher blood alcohol concentrations. Those physiological differences, combined with the sharp increase in alcohol use and binge drinking, have made women particularly vulnerable to alcohol-related illnesses. 'Historically, there's been differences in prevalence rates [of alcohol use] between men and women. And essentially, that gap has now closed and the ratio between men and women's drinking is almost at 1 to 1,' said Sherry McKee, director of the Yale SCORE Program on Sex Differences in Alcohol Use Disorder. Changes in women's lifestyles have created increasing opportunities to consume alcohol, McKee said. Today's young adults drink less compared with previous generations, but there are now more women in college than men — and college is generally associated with increased alcohol consumption, she said. 'You pair that with the fact that women are delaying childbirth, delaying marriage — it just gives more space for women to continue drinking in the post-college years,' McKee said. Women's heavy alcohol consumption is most common in midlife, said Katherine Keyes, an epidemiology professor at Columbia University's Mailman School of Public Health. Some researchers attribute the trend to stress or office drinking culture, but Keyes said the main reason women are drinking more is for fun. She noted that wine and spirits are often marketed to women as luxury goods or methods of relaxation. Experts said more awareness of the health risks of drinking could help encourage women to scale back. 'It isn't the case that every single person who drinks heavily will get liver disease from it. But we do know that a proportion of those folks do — about 25 to 30%,' said Dr. Jessica Mellinger, a senior staff physician at Henry Ford Health, a Michigan-based health system. The more a person drinks, she added, the greater likelihood they have of getting alcohol-related liver disease of any stage. The study published Wednesday found that heavy drinkers are developing alcohol-related liver disease at more than double the rate compared with 20 years ago. The researchers suspect that's because people vulnerable to liver disease — including women and those with obesity or diabetes — are drinking more compared with decades past. 'The modern American drinker looks different than it did 20 years ago,' said Dr. Brian Lee, the study's lead author and a hepatologist at Keck Medicine of the University of Southern California. The researchers used data from a national, government-led survey to measure drinking habits and liver health in the U.S. They characterized heavy drinkers as men who consumed at least 30 grams of alcohol per day — roughly two standard drinks — and women who consumed at least 20 grams per day. Among heavy drinkers, the risk of significant liver damage more than doubled over a 22-year period, from nearly 2% in 1999-2004 to more than 4% in 2013-20. The rate of metabolic syndrome — conditions like obesity or high blood pressure that increase the risk of heart disease, diabetes and stroke — among heavy drinkers also increased during that time, from 26% to nearly 38%. Both obesity and Type 2 diabetes can cause fat to build up in the liver, thereby elevating the risk of liver disease. 'It could be the situation of a perfect storm. We have an increase in alcohol consumption … alongside changing prevalence of these other [health] conditions,' Keyes said. Lee said it's important for people to be honest with their doctors about their alcohol intake, so that doctors can decide whether to screen them for liver disease. 'Your risk of liver disease might be higher than you think,' he said. 'The reality is that liver disease is silent, and most people — even with cirrhosis, which is end-stage liver disease — have no symptoms at all. I always say it's a blessing and a curse that you need very little healthy amounts of liver to feel perfectly fine.' Keyes said women in particular tend to wait longer to seek medical care for heavy drinking due to social stigma. 'It's really becoming this hidden epidemic where women wait too long to see someone about a really serious, alcohol-related condition,' she said. This article was originally published on Solve the daily Crossword
Yahoo
20 minutes ago
- Yahoo
START and Advarra Unite to Deliver Unmatched Speed, Quality, and Predictability for Early-Phase Oncology Trials
START enhances its global leadership by integrating Advarra's advanced regulatory and technology solutions, creating a seamlessly connected site network to accelerate trials and relieve pressure on the oncology drug development ecosystem SAN ANTONIO, July 24, 2025 /PRNewswire/ -- The START Center for Cancer Research (START), the leading global community-based early-phase oncology research network, today announced a strategic partnership with Advarra, the premier provider of clinical research solutions for sites and institutions, including ethics oversight, technology, and consulting and professional services. This collaboration significantly advances START's leadership position in oncology research by creating an end-to-end, patient-centric clinical trial workflow across its growing network of sites, driving standardization, data efficiency, compliance, and consistent high quality. Through this strategic alliance, START's global site network will leverage Advarra's comprehensive portfolio of products and services. Advarra will be START's preferred provider for Independent Review Board (IRB) and Institutional Biosafety Committee (IBC) services. Additionally, START will leverage new technologies that seamlessly integrate with Advarra's OnCore Clinical Trial Management System (CTMS), which supports over 85% of NCI-designated cancer centers and has been actively used to improve operational efficiency across START's network since 2024. Initially, START will deploy Advarra's CTMS-integrated electronic regulatory management system, called eReg, for end-to-end, secure management of regulatory documents across all sites participating in a trial. "Oncology drug development companies are under intense pressure to deliver innovative treatments to patients swiftly and reliably," said Nick Slack, MBE, Chairman and CEO of START. "By partnering with Advarra, we are building a truly interconnected ecosystem, leveraging the best technology and regulatory expertise in the industry, and adopting Advarra's standardized workflows and integrated platforms will significantly enhance our operational efficiency, compliance, and quality—ensuring that we not only accelerate the delivery of breakthrough therapies to patients but also uphold the highest standards of patient safety. We're proud to advance our mission with a partner equally committed to excellence." Implementation of Advarra's integrated solutions across START's global network is well underway, with OnCore and Advarra's IRB and IBC services already actively in use. This partnership marks a significant milestone in START's continued investment in infrastructure, operational excellence, and its mission of delivering "Hope Through Access," aimed at connecting patients, physicians, and advocacy groups with community-based cancer trials. "Advarra is honored to support START in fulfilling its mission of bringing cutting-edge cancer treatments to patients," said Gadi Saarony, CEO of Advarra. "With deep expertise in oncology research, decades-long partnerships with leading cancer centers, and a proven track record of delivering solutions for regulatory compliance and operational excellence, our role is to help remove barriers to research—streamlining the path from discovery to care. We're proud to partner with START as it expands its reach and impact around the world." About The START Center for Cancer Research Deeply rooted in community oncology centers globally, The START Center for Cancer Research provides access to specialized preclinical and early-phase clinical trials of novel anti-cancer agents. START sites have conducted over 1,000 early-phase trials, including studies for 45 therapies approved by the FDA or EMA. Representing the world's largest roster of early-phase Principal Investigators across ten clinical trial sites, START accelerates the journey from trials to treatments, delivering hope to patients, families, and physicians worldwide. Learn more at About Advarra Advarra breaks the silos that impede clinical research, aligning patients, sites, sponsors, and CROs in a connected ecosystem to streamline trials. Advarra is number one in research review services, a leader in site and sponsor technology, and is trusted by the top 50 global biopharma sponsors, top 20 CROs, and 50,000 site investigators worldwide. Advarra solutions enable collaboration, transparency, and efficiency to optimize trial operations, ensure patient safety and engagement, and reimagine clinical research while improving compliance. For more information, visit Media Contacts: STARTLauren Panco, VP Marketing | 609-216-4920 | Osborne, PR Consultant | lisa@ AdvarraMichelle Valentine, PR Consultant, michellevalentinepr@ / mediarelations@ View original content to download multimedia: SOURCE The START Center for Cancer Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
20 minutes ago
- Yahoo
Novavax's H5N1 Vaccine Candidate Demonstrates Immunogenicity in Preclinical Study
Peer-reviewed data shows Novavax's H5N1 vaccine candidate demonstrated immunogenicity against currently circulating variants following either single or two-dose administration Potential for single intranasal or intramuscular dose could differentiate Novavax's vaccine as part of pandemic emergency preparedness efforts GAITHERSBURG, Md., July 24, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced preclinical data demonstrating that Novavax's H5N1 avian pandemic influenza vaccine candidate, leveraging Novavax's recombinant, protein-based nanoparticle technology and Matrix-M® adjuvant, induced robust immune responses by either single or two-dose intranasal (IN) or intramuscular (IM) administration in nonhuman primates. Results were published in Nature Communications. "These preclinical results underscore the promise and potential of our pandemic influenza program as well as the strength of our technology platform and our ability to deliver against our corporate growth strategy," said Ruxandra Draghia-Akli, MD, PhD, Executive Vice President and Head of Research and Development, Novavax. "Our R&D pipeline focuses on delivering assets ready for partnership and prioritizing areas of unmet medical need, including vaccines for avian pandemic influenza, where we see clear potential advantages for our technology compared with other vaccines that are licensed or in development." Results showed that a single dose administered by either IN or IM routes induced neutralizing antibody responses (IN: 1:54; IM: 1:1,160), at or above the 1:40 titer generally considered to be a protective antibody response. The data showed even higher levels of immunity after two doses. These data suggest that even a single IN dose has the potential to provide protective immunity in individuals previously exposed to seasonal influenza either by vaccination or infection. Further, data showed Novavax's H5N1 vaccine candidate elicited broad antibody responses, suggesting the potential to protect against forward-drift variants from currently circulating strains of the H5N1 virus. H5N1, a highly pathogenic and dynamic avian pandemic influenza virus, is of concern due to its potential to mutate into a strain adapted for sustained human-to-human transmission. To date, there have been 70 confirmed total reported human cases in the U.S., and one death associated with H5N1 avian pandemic influenza infection.1 As of July 2025, no reported cases in the U.S. have been proven to result from human-to-human transmission. As part of its corporate growth strategy, Novavax is making targeted investments in early-stage development programs to create value. Novavax intends to pursue funding, partnership and licensing opportunities for its H5N1 vaccine candidate. About Novavax Novavax, Inc. (Nasdaq: NVAX) tackles some of the world's most pressing health challenges with its scientific expertise in vaccines and its proven technology platform, including protein-based nanoparticles and its Matrix-M adjuvant. The Company's growth strategy seeks to optimize its existing partnerships and expand access to its proven technology platform via research and development (R&D) innovation, organic portfolio expansion in infectious disease and beyond, and forging new partnerships and collaborations with other companies. Please visit and LinkedIn for more information. Forward-Looking Statements Statements herein relating to the future of Novavax, its operating plans and prospects, its partnerships, and the potential for a single intranasal or intramuscular dose differentiating Novavax's H5N1 vaccine, are forward-looking statements. Novavax cautions that these forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, challenges pursuing additional partnership opportunities; challenges satisfying, alone or together with partners, various safety, efficacy, and product characterization requirements, including those related to process qualification, assay validation and stability testing, necessary to satisfy applicable regulatory authorities; challenges or delays in conducting clinical trials or studies for its product candidates; challenges or delays in obtaining regulatory authorization for its product candidates, including for future COVID-19 variant strain changes, its CIC vaccine candidate, its stand-alone influenza vaccine candidate or other product candidates; manufacturing, distribution or export delays or challenges; Novavax's substantial dependence on Serum Institute of India Pvt. Ltd. and Serum Life Sciences Limited for co-formulation and filling Novavax's COVID-19 vaccine and the impact of any delays or disruptions in their operations; difficulty obtaining scarce raw materials and supplies including for its proprietary adjuvant; resource constraints, including human capital and manufacturing capacity; constraints on Novavax's ability to pursue planned regulatory pathways, alone or with partners; challenges in implementing its global restructuring and cost reduction plan; challenges in obtaining commercial adoption and market acceptance of its updated COVID-19 vaccine or any COVID-19 variant strain containing formulation, or for its CIC vaccine candidate and stand-alone influenza vaccine candidate or other product candidates; challenges meeting contractual requirements under agreements with multiple commercial, governmental, and other entities, including requirements to deliver doses that may require Novavax to refund portions of upfront and other payments previously received or result in reduced future payments pursuant to such agreements and challenges in amending or terminating such agreements; challenges related to the seasonality of vaccinations against COVID-19; challenges related to the demand for vaccinations against COVID-19 or influenza; challenges in identifying and successfully pursuing innovation expansion opportunities; Novavax's expectations as to expenses and cash needs may prove not to be correct for reasons such as changes in plans or actual events being different than its assumptions; and those other risk factors identified in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Novavax's Annual Report on Form 10-K for the year ended December 31, 2024, and subsequent Quarterly Reports on Form 10-Q, as filed with the Securities and Exchange Commission (SEC). We caution investors not to place considerable reliance on forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at and for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of the statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties. Contacts: Investors Luis Sanay, CFA 240-268-2022 ir@ Media Giovanna Chandler (844) 264-8571 media@ References U.S. Centers for Disease Control and Prevention. H5 Bird Flu: Current Situation. 2025. Available at: View original content to download multimedia: SOURCE Novavax, Inc.
